The recent report of successful combined use of AURKA CD inhibitors and ATR inhibitors in MYCN amplified neuroblastoma [48] strengthens the potential value of using compounds disrupting both AURKA activity and the interaction with N-Myc for the treatment of this highly aggressive tumor type. Here, MYCN is linked to neoplasm.